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Summary
TGF- ligands stimulate diverse cellular differentia-
tion and growth responses by signaling through type
I and II receptors. Ligand antagonists, such as fol-
listatin, block signaling and are essential regulators
of physiological responses. Here we report the struc-
ture of activin A, a TGF- ligand, bound to the high-
affinity antagonist follistatin. Two follistatin molecules
encircle activin, neutralizing the ligand by burying
one-third of its residues and its receptor binding sites.
Previous studies have suggested that type I receptor
binding would not be blocked by follistatin, but the
crystal structure reveals that the follistatin N-terminal
domain has an unexpected fold that mimics a univer-
sal type I receptor motif and occupies this receptor
binding site. The formation of follistatin:BMP:type I
receptor complexes can be explained by the stoichio-
metric and geometric arrangement of the activin:
follistatin complex. The mode of ligand binding by fol-
listatin has important implications for its ability to
neutralize homo- and heterodimeric ligands of this
growth factor family.
Introduction
The transforming growth factor β (TGF-β) ligands con-
trol diverse physiological processes important to or-
ganismal development, reproduction, and health. Dur-
ing embryogenesis, TGF-β ligands act as morphogens,
establishing cell fate asymmetries along dorsal/ventral
and anterior/posterior axes (Yamamoto and Oelge-
schlager, 2004). In the adult, TGF-β signaling regulates
reproductive functions, wound healing, tissue regener-
ation, and immune system function (Bilezikjian et al.,
2004; Lin et al., 2003; Tsuchida, 2004). Recently, TGF-β
signals have been shown to maintain embryonic stem
cells in a pluripotent, undifferentiated state (Beattie et
al., 2005; James et al., 2005). Aberrant signaling is
therefore associated with many human health issues,
including cancer, autoimmunity, birth defects, and infer-*Correspondence: tedj@northwestern.edu
4Present address: Department of Molecular Genetics, Biochemis-
try, and Microbiology, University of Cincinnati, 231 Albert Sabin
Way, Cincinnati, Ohio 45267.tility (Chang et al., 2002; Kaklamani and Pasche, 2004;
Siegel and Massague, 2003; Tsuchida, 2004).
The TGF-β superfamily includes three major ligand
subfamilies—the TGF-βs, the activin/inhibins, and the
bone morphogenetic proteins (BMPs) (Dennler et al.,
2002; Shi and Massague, 2003). Ligands typically form
disulfide-linked homodimers with a characteristic cys-
teine-knot fold, although heterodimers and non-cova-
lently-linked dimers exist (Sebald et al., 2004; Sun and
Davies, 1995). Ligands signal by forming complexes
with type I and type II serine/threonine kinase recep-
tors, allowing constitutively active type II receptor ki-
nases to phosphorylate and activate neighboring type
I receptors (Sebald et al., 2004; Shi and Massague,
2003). Activated type I receptors phosphorylate SMAD
proteins, which subsequently translocate to the nu-
cleus and control gene expression (Shi and Mas-
sague, 2003).
Extracellular antagonists of TGF-β signaling are im-
portant regulators of this signal transduction pathway
(Canalis et al., 2003; Gumienny and Padgett, 2002; Pan-
gas and Woodruff, 2000; Yamamoto and Oelgeschlager,
2004). Antagonists, including follistatin, noggin, chor-
din, DAN/Cerberus, and others, bind ligands with high
affinity and interfere with receptor engagement, thereby
regulating many physiological responses. For example,
in early embryonic development, antagonists produced
in Spemann’s Organizer are critical for the establish-
ment of proper BMP morphogen gradients (Harland
and Gerhart, 1997). It has recently been shown that the
simultaneous depletion of follistatin, noggin, and chor-
din in Xenopus tropicalis leads to a dramatic loss of
embryonic dorsalization (Khokha et al., 2005). Thus,
these three TGF-β antagonists play an essential role in
morphogenesis, with overlap in their functions and li-
gand specificities.
Individual TGF-β antagonists do, however, have dis-
tinct biological functions. Follistatin knockout mice ex-
hibit defects in size and skeletal and muscle develop-
ment, and they die shortly after birth (Canalis et al.,
2003; Chang et al., 2002; Matzuk et al., 1995). Follistatin
was first identified as a potent inhibitor of activin (Kd
w45 pM), but it also binds other ligands, including in-
hibin, BMPs 2, 4, 6, 7, 11, and 15, and myostatin, with
lower affinities (Abe et al., 2004; Canalis et al., 2003;
Gumienny and Padgett, 2002). The phenotypic effects
in follistatin knockout mice are more wide-ranging than
those in activin knockout mice, consistent with fol-
listatin regulation of the lower-affinity TGF-β ligands in
vivo (Canalis et al., 2003; Chang et al., 2002).
In order to provide a structural basis for understand-
ing the specificity and function of TGF-β ligands and
their interactions with receptors and antagonists, we
have undertaken X-ray crystallographic studies of ac-
tivin A complexes. We previously determined the crys-
tal structure of activin A bound to the high-affinity type
II receptor, ActRIIB, revealing unusual flexibility in the
ligand at its putative type I receptor binding interface
(Thompson et al., 2003). We have now determined the
crystal structure of activin A bound to the extracellular
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536antagonist follistatin. While previous studies have sug-
gested that follistatin might act by inhibiting type II, but
not type I, binding to ligands (Fischer et al., 2003; Ie-
mura et al., 1998; deWinter et al., 1996), the crystal
structure of the complex reveals that both receptor
binding sites are blocked. The follistatin N-terminal do-
main occupies the type I receptor binding site, exhibit-
ing a helical structural motif that is conserved in type I
receptors and contributing nearly half of the contact
surface. The follistatin:activin crystal structure provides
new insights into the modular architecture of the fol-
listatin molecule, novel structural features of the activin
ligand, and a basis for understanding follistatin inhibi-
tion of other TGF-β superfamily members.
Results and Discussion
Overview of the Follistatin:Activin Complex
Three isoforms of follistatin have been identified, end-
ing at residues 288 (FS-288), 303 (FS-303), and 315 (FS-
315) (Schneyer et al., 2004). FS-288 binds with w10-
fold higher affinity to activin than FS-315 (Hashimoto et
al., 2000) and also binds heparan sulfate, localizing it
to cellular surfaces. FS-315 does not bind heparan sul-
fate and is the primary soluble form observed in serum
(Schneyer et al., 2004). Purified FS-288 was cocrystal-
lized with activin A and the structure (Figures 1A and
1B) solved to 2.8 Å (Table 1 and Supplemental Data
available with this article online).
In the complex, two FS-288 molecules wrap around
the activin dimer (Figure 1A), burying 3000 Å2 of the
ligand surface and contacting 39 of 116 residues in
each subunit. Activin A adopts an extended conforma-
tion, with its curved β strands (fingers) extending from
the central dimer interface (wrist) region in opposite di-
rections. Flexible residues of the activin wrist region,
not observed in previous activin structures (Greenwald
et al., 2004; Thompson et al., 2003), are well ordered in
the complex.
The two FS-288 molecules adopt C-clamp-like con-
formations, with each extending around an activin sub-
unit, forming head-to-tail contacts between their N- and
C-terminal domains. FS-288 contains an N-terminal do-
main (ND) and three follistatin domains (FSD1, FSD2,
and FSD3), which are further subdivided into EGF-like
and Kazal protease inhibitor-like domains (Figure 1;
Keutmann et al., 2004). The FS N-terminal domain con-
tacts the wrist region of one activin A subunit and the
concave fingers of the second (Sebald et al., 2004).
FSD1, FSD2, and FSD3 contact only one activin sub-
unit, extending around its outer knuckles and fingertips.
The EGF domain of FSD1 projects away from activin
A, linking the N-terminal and C-terminal domains, and
exhibits the highest temperature factors, indicating that
it is the most flexible region of the complex. FSD2 con-
tacts the ligand knuckles and fingertips, while FSD3
projects upwards from the complex, forming contacts
with ND of the second FS-288.
Follistatin domains, comprised of EGF and Kazal
subregions, have been identified in other proteins, in-
cluding follistatin-related protein, BM-40, agrin, tomor-
egulin, and complement proteins C6 and C7 (Innis and
Hyvonen, 2003; Sasaki et al., 1998). Previous structural
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iigure 1. Overview of the Follistatin:Activin A Complex
A) Ribbon diagram of the follistatin:activin complex (top view). Ac-
ivin is shown in red and the finger, wrist, and knuckle regions are
ndicated. One follistatin monomer is shown in green, shaded from
he N terminus (dark green) to the C terminus (light green). The
ther follistatin monomer is shown in blue, shaded from the N ter-
inus (dark blue) to the C terminus (light blue).
B) Ribbon diagram of the follistatin:activin complex colored as in
A) but rotated 90° (side view).
C) Schematic of the follistatin domain structure.
D) Overlay of the individual follistatin domains 1–3 using their Ka-
al-like domains. The EGF domains are labeled with a subscript
orresponding to the follistatin domain number, and the interdo-
ain linkers are indicated. The interdomain anchoring cysteines
121, 196, 273) are shown in their respective disulfide bonds, with
he backbone highlighted in blue.tudies of isolated FSD1 identified a potential heparan
ulfate binding site and revealed that the EGF and Ka-
al subdomain arrangement differs from that in BM-40
Innis and Hyvonen, 2003). In the activin complex, the
SD1 conformation is similar to that observed for the
solated domain, placing the heparan sulfate binding
Activin:Follistatin Structure
537Table 1. Crystallographic Data and Refinement Statistics
Data Collection Native/IrCl6
Resolution (Å) 19.35–2.8
# of observations 157,008
# of unique reflections 23,416
Completeness (%) 99.2
Redundancy 4.9
Rsym (%) 5.2 (51.8)
I/σI 11.7/(1.5)
Refinement
Resolution (Å) 19.35–2.8
Reflections (total/free)a 23,381 (1,177)
R factor (Rfree), % 26.6 (29.7)
Atoms (total/protein) 6,061 (5,867)
Rmsd
Bonds (Å) 0.011
Angles (°) 1.96
B factors (Å2)
Activin A, chain 1 68.4
Activin A, chain 2 57.9
FS-288, chain 1 68.0
FS-288, chain 2 81.2
aExcluding systematic absences.sites on the exterior sides of the complex. FSD2 and
FSD3, however, adopt two different subdomain config-
urations (Figure 1D), where the EGF regions fold back
onto the Kazal domain, forming a more compact T-like
shape. Two disulfide bonds within the EGF motif main-
tain its rigidity, while a third disulfide bond links the two
subdomains, with one of the cysteines (121, 196, and
273) anchoring the three differing FSD conformations
(Figure 1D).
Two Distinct Contact Interfaces
Each FS-288 buries 1500 Å2 of the activin surface, with
the majority on only one subunit (1250 Å2). Follistatin
contacts two contiguous surfaces on activin (Figure 2).
One surface (site 1) is formed by activin residues from
the concave β strand fingers of one subunit and the
helical wrist region of the second. The second surface
(site 2) includes residues in the convex (knuckle) side
of the activin β strands and extends around the β strand
fingertips (Figures 2A and 2B). FS-288 surrounds the
ligand in an embrace that occludes more of the ligand
surface than the two discrete contact sites.
Site 1 contacts are formed by FS-288 ND, while site
2 interactions are formed by the FSD1 Kazal and FSD2
domains. The EGF domain of FSD1 does not contact
activin, opening a small gap between FS-288 and ac-
tivin that separates the two interaction sites on both
proteins. FS-288 ND buries a total of 670 Å2: 430 Å2 on
the wrist region of one subunit and 240 Å2 on the β
strands of the other. FSD1 buries 200 Å2 of surface on
the activin knuckle region and FSD2 buries 610 Å2 on
the knuckles and fingertips of a single subunit. FSD3
makes few contacts to activin, burying less than 15 Å2
of the ligand surface.
On activin, the site 1 interaction buries hydrophobic
residues on the concave surface of one monomer (W25,
W28, M91, Y93, and I105) and two helical regions of the
second monomer. One of the helices (α , residues 57–268) is long and observed in other TGF-β family ligands
(Sebald et al., 2004; Sun and Davies, 1995), while the
shorter helix (α#, residues 46–50) is unique to activin in
this complex (Figure 2E). Follistatin contacts residues in
the shorter helix (H47, I48, and G50) and the interhelical
linker (T51 and S52) and along the longer conserved
helix (F58, T61, and H65). On FS-288, these contacts
are made exclusively by the N-terminal domain.
Site 2 is formed by hydrophobic residues on the con-
vex surface of activin A (A31, P32, I30, L92, Y94, I100,
and K102) that pack with hydrophobic follistatin resi-
dues (L105, V151, Y159, and V161) on FSD1 and FSD2.
In addition, the convex patch forms several hydrogen
bonds and electrostatic interactions. For example, the
FSD2 side chain of R192 is locked into a groove on
activin through a clamp formed by D27 and Q98.
Origin of Follistatin Specificity
FS-288 binds activin A with very high affinity (50 pM),
the closely related activin B isoform with w10-fold
lower affinity, and many BMP ligands with lower affini-
ties ranging from 2 to 80 nM. However, follistatin does
not bind TGF-β ligands (Amthor et al., 2002, 2004; Glis-
ter et al., 2004; Hashimoto et al., 2000; Iemura et al.,
1998; Otsuka et al., 2001; Schneyer et al., 2003). Based
on their sequences and follistatin affinities, we placed
these ligands into four groups: the nonbinding TGF-β
ligands; the activins; the majority of known BMP li-
gands (2, 4, 5, 6, 7, 15); and myostatin and BMP11.
Surprisingly, of the 39 activin residues buried in the
complex with follistatin, 12 are conserved or conserva-
tively substituted across binding and nonbinding li-
gands (blue, Figures 2E and 3A). These residues are
centrally clustered at both follistatin binding interfaces
and include many hydrophobic or aromatic residues
(F17, W25, W28, P32, G34, Y35, M89, L92, Y93, Y94,
I105, and I109). Because these core residues are pre-
sent in the nonbinding TGF-βs, they cannot determine
the follistatin binding specificity, but instead likely form
a common set of hydrophobic contacts in the binding
ligands.
The conserved residues define one class of ligand
interface residues, and we divided the remaining ones
into three additional categories: (1) interface residues
that are conserved in the majority of the follistatin bind-
ing ligands (activins and BMPs), but not in the nonbind-
ing TGF-βs (yellow, Figures 2E and 3A); residues that
are conserved in activin A and/or B, but differ in the
BMPs and TGF-βs (red, Figures 2E and 3A); and those
that are highly variable (magenta, Figures 2E and 3A).
Interestingly, myostatin, whose affinity for follistatin is
intermediate between activin A and BMP ligands (w0.5
nM) shows elements of the activin-unique group and
the BMP/activin-conserved group, in addition to myo-
statin-specific sequence changes (Figure 2E).
These four sequence groups provide insights into fol-
listatin binding determinants when mapped onto the
activin structure (Figure 3A). While the conserved (blue)
residues provide a core set of interactions in both sites
1 and 2, the amino acids common to activins and BMPs
(but not TGF-βs) cluster to the edges of the conserved
residues, defining an extended, common contact re-
gion for follistatin that differs in TGF-β ligands. In the
Developmental Cell
538Figure 2. Contact Surfaces and Residues in
the Complex
(A and B) Surface of the activin dimer show-
ing the regions of follistatin binding. The sur-
face is colored by the per-residue buried sur-
face area for each interacting atom (low
[blue] to high [red]).
(C and D) Surface of a single follistatin mo-
nomer showing the regions that interact with
activin. The surface is colored by the area
buried for each residue as in (A) and (B).
(E) Sequence alignment of TGF-β ligands.
Residues involved in type I receptor, type II
receptor, and follistatin interfaces are indi-
cated above the alignment as circles, with
the relative buried surface indicated by the
number of colored quadrants. The second-
ary structure of activin is represented below
the alignment (yellow, strands; blue, helices).
Background residue coloring is as in Figure
3A, with boxes for the highly variable ligands.
Black circles mark the activin sequence every
10 residues and the last residue number of
each ligand is shown.TGF-βs, many of the amino acid differences in these
peripheral residues lead to electrostatic charge switch-
ing (residues 27, 30, 31, 87, 95, 96, 101, and 103) that
could significantly disrupt follistatin binding to the core
hydrophobic residues (Figure 2E).
Many of the activin-specific residues map to the wrist
region of the structure (red, Figure 3A), including resi-
dues near the N terminus and the α# and α2 helices.
This group borders one edge of the follistatin site 1 in-
teraction, forming contacts with FS-288 ND. The ligand
sequence differences include variations in chain length
at both the N terminus and in the polypeptide segment
preceding the common α2 helix.
The final category of highly variable residues (ma-
genta, Figure 3A) reveals a cluster at the activin finger-
tips, but also along the periphery of the two binding
sites, which may also be important for the high-affinity
interactions with activin A or for tailoring the affinities
of the different binding ligands. For example, follistatin
R192 interacts on activin A with the highly conserved
D27 and the variable Q98 ligand residues. Q98 changes
to tyrosine in activin B, glutamic acid in myostatin and
BMP-2, and serine in BMP-5, 6, 7.
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esidues as compared to other ligands, but it also ex-
ibits unique structural features. The structure of ac-
ivin A bound to ActRIIB revealed flexibility in the activin
imer accompanied by disorder in the wrist region resi-
ues (Figure 3B; Thompson et al., 2003), subsequently
onfirmed in another crystal form (Greenwald et al.,
004). Activin opens to an extended conformation in
omplex with follistatin, accompanied by the ordering
nd folding of the wrist region helices (Figure 3B). The
ollistatin bound activin does, however, adopt a dis-
inct, less-extended conformation as compared to
ther TGF-β ligands (Figure 3C) and contains the
nique α# helix (Figure 3D), which contacts follistatin.
his activin-specific α# helix is likely an important struc-
ural determinant of type I receptor binding specificity
s well. In BMPs it is replaced by a shorter, more rigid
rehelix loop that partially clashes with a superim-
osed follistatin.
ollistatin Blocks Both Receptor Binding Sites
ollistatin competitively inhibits binding of activin to its
igh-affinity type II receptors, effectively neutralizing
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539Figure 3. Sequence and Structural Determi-
nants of Follistatin Binding
(A) Activin residues that are buried from
solvent upon binding follistatin are shown col-
ored by the level of sequence conservation.
Blue, residues conserved or conservatively
substituted in activins/BMPs and TGF-β li-
gands; yellow, residues conserved in activins
and BMPs but not TGF-βs; red, residues con-
served in activins A and B; magenta, all other
residues.
(B) Superposition of three activin A struc-
tures. Pink and light yellow, activin A in com-
plex with ActRIIB; blue, activin A bound to
follistatin. The straight arrows point to break-
points in the chain trace for previous activin
A structures.
(C) Superposition of activin A with other
TGF-β ligands.
(D) Close-up view of the common α-helical
wrist region in TGF-β ligands (activin A in
blue). Note the common, longer α2 helix and
the shorter, unique activin α# helix.activin signaling (Schneyer et al., 2003). Since activin
binding to type I receptors is of low affinity and depen-
dent upon type II receptor binding, it has remained un-
clear whether follistatin blocks the type I receptor in-
teraction directly. BMP ligands, which bind with high
affinity to their type I receptor (BMP-RI), can simulta-
neously bind both follistatin and BMP-RI, suggesting
that follistatin does not block type I receptor binding
(Canalis et al., 2003; Gumienny and Padgett, 2002; Ie-
mura et al., 1998). In contrast to follistatin, the BMP
antagonist noggin does not form cocomplexes with
BMP and BMP-RI, and in the noggin:BMP-7 crystal
structure, noggin sterically blocks both type I and type
II receptor binding sites (Canalis et al., 2003; Groppe et
al., 2002; Gumienny and Padgett, 2002; Iemura et al.,
1998). These observations have led to the proposal that
the mechanism of follistatin inhibition, in particular for
BMP ligands, differs from that of noggin, with the for-
mation of inhibitory complexes containing both BMP
and its type I receptor (Iemura et al., 1998).
The receptor binding sites on TGF-β ligands have
been identified by both structural and mutagenesis
studies. Activin and BMPs engage type II receptors on
the knuckle regions of the TGF-β fold (Greenwald et al.,
2003, 2004; Thompson et al., 2003), while type I recep-
tors are thought to bind at the dimer interface, contact-
ing the helical wrist region of one subunit and the con-
cave fingers of the other (Kirsch et al., 2000; Sebald et
al., 2004). A model for an activin signaling assembly
can be generated using the extended activin structure
bound to follistatin, the crystal structure of the activin:
ActRIIB complex (Thompson et al., 2003), and the
BMP-2:BMP-RIA complex (Kirsch et al., 2000) (Figure
4A). Mutagenesis studies indicate that activin type I re-
ceptor binding occurs similarly to BMP-RIA binding to
BMP-2, in support of this model for the signaling com-
plex (Harrison et al., 2004; R.W.C., submitted).
The activin:FS-288 structure shows that follistatin
blocks both the type I and type II receptor sites (Figure4B). In particular, the N-terminal domain of follistatin
(site 1, above), which is required for binding to activin
(Keutmann et al., 2004), occupies the type I receptor
binding site. The type II receptor binding site is blocked
by both FSD1 and FSD2 (site 2, above), and overall ac-
cess to the ligand lateral surfaces is occluded by FS-
288 (Figure 4B).
On activin, the interaction surfaces for receptors and
follistatin are overlapping but not identical. Follistatin
buries approximately 75% of the surface of the type II
receptor interface (blue, Figures 4C and 4D), except for
a portion along the top of the ligand (yellow, Figures 4C
and 4D). At the modeled type I receptor interface, the
majority of the binding surface is predicted to be cov-
ered by the FS-288 N-terminal domain (red, Figures 4C
and 4D). Follistatin interactions extend beyond the
known receptor interfaces (green, Figures 4C and 4D),
forming contacts in the fingertip region and the lateral
edges of the dimer interface.
The Follistatin N-Terminal Domain Mimics a Type I
Receptor by Using a Modified TB Domain
Previous functional studies have demonstrated the im-
portance of the follistatin ND in activin binding (Keut-
mann et al., 2004), but sequence analysis did not reveal
homology to known structures. A structural database
search with the ND structure reveals that it adopts the
TB domain fold, previously identified in latent TGF-β
binding proteins (LTBPs) and fibrillins (Figure 5A; Lack
et al., 2003; Lee et al., 2004; Yuan et al., 1997). LTBPs
regulate TGF-β signaling by forming a latent complexes
with the cleaved TGF-β proproteins (Gumienny and
Padgett, 2002; Rifkin, 2005), and fibrillins are multido-
main proteins of the extracellular matrix that are also
implicated in regulating TGF-β signaling (Boileau et al.,
2005). Fibrillins contain nine copies of the TB or related
TB-hydrid (TH) domain, while LTBPs contain four (Lack
et al., 2003; Lee et al., 2004; Yuan et al., 1997). The
typical TB domain consists of w60–70 residues with 4
Developmental Cell
540Figure 4. Follistatin Binds to Both Receptor
Binding Sites
(A) Model of a putative signaling complex
composed of two type I receptors (based on
the BMP-RI:BMP-2 complex), two type II re-
ceptors, and the extended activin A
structure.
(B) Surface representation of follistatin
bound to activin (ribbons). Follistatin blocks
both receptor binding sites.
(C) Surface representation of the activin di-
mer showing the overlapping but noniden-
tical interaction sites for receptors and fol-
listatin (top view). Buried surface unique to
follistatin is shown in green; the surface
unique to ActRIIB is in yellow; the surface
common to follistatin and ActRIIB is in blue.
The buried surface unique to the modeled
type I receptor is shown in orange, and the
surface common to follistatin and the mod-
eled type I receptor is in red.
(D) Side view of the activin dimer surface
colored as in (C).and TGFB-RI receptors and is replaced by methionine
Figure 5. Follistatin ND Is a Modified TB
Domain that Mimics Type I Receptor
(A) Overlay of the follistatin, fibrillin (yellow),
and LTBP (green) TB domains, showing the
prominent helical insertion in follistatin.
(B) Sequence alignment of fibrillin, LTBP, and
follistatin TB and TH domains. Disulfide
bond arrangements for the TB domains are
shown above the sequences and the sec-
ondary structure of the follistatin ND is
shown below (yellow, strands; blue, helices).
The inserted sequence region of follistatin
and the exposed F47 are highlighted. Black
circles mark the follistatin sequence every
10 residues.
(C and D) Superposition of the follistatin and
type I receptor structures and complexes,
revealing the similarities in the placement of
the helical scaffold and phenylalanine rela-
tive to the ligand.
naling by a unique mechanism, since it binds simulta-disulfide bonds forming a tightly crosslinked α-helical
and β sheet structure.
While the overall TB domain fold is conserved in fol-
listatin ND, it contains only three of the four disulfide
bonds and a large insertion between the fourth and fifth
cysteines (Figure 5B). This insertion forms a unique α
helix that projects away from the compact TB domain
(Figure 5A). We have not been able to identify other TB
domains that contain the follistatin ND helical insertion.
This unique ND helix mimics the BMP type I receptor
(Figures 5C and 5D). In both structures, an α helix pres-
ents an exposed phenylalanine (F85 in BMP-RIA and
F47 in FS-288), which interacts similarly with hydropho-
bic residues on the ligand. F85 was previously iden-
tified as a key feature of type I receptors (Kirsch et al.,
2000). It is conserved in BMP-RIA, BMP-RIB, ActRIB,
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In ActRI. In FS-288, the TB domain scaffold supports
he unique helical insert, while in BMP-RIA, the helix is
horter and presented on the distinct β sheet fold of
he receptor (Figure 5D).
The FS-288 and BMP-RIA helices contact the wrist
egion of the ligand dimer, with F85 of BMP-RIA insert-
ng deeper into BMP-2. The substitution of N59 in BMP-2
y F58 in activin fills in a hydrophobic hole in BMP-2
nd produces a shallower surface in activin, leading to
he displacement of the FS-288 F47 and helix. The con-
ervation of this structural feature across type I recep-
ors and ND suggests that this interaction is conserved
n follistatin:BMP complexes.
iffering Modes of TGF- Ligand Inhibition
t has been proposed that follistatin inhibits BMP sig-
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541neously to both BMP and BMP-RI, while noggin and
chordin completely block receptor binding (Iemura et
al., 1998). The follistatin:activin A structure reveals that
type I receptor binding is obstructed in the 2:1 complex
by ND interactions. However, in a 1:1 follistatin:BMP
complex, BMP could interact with BMP-RI through its
second type I receptor binding site (Figure 6). Since
BMP affinities for type I receptor and follistatin are
comparable (Iemura et al., 1998), the formation of such
complexes are thermodynamically accessible. An alter-
native possibility is that BMP-RI displaces ND, leaving
follistatin bound only through site 2 interactions. This
seems less likely since ND is a structural mimic of
BMP-RI, forming nearly 50% of the follistatin interface,
and is critical for activin binding (Keutmann et al.,
2004), but the importance of ND in BMP binding needs
to be established. In either case, BMP signaling may
be disrupted not only by the formation of a neutralized
2:1 follistatin complex, but also by the formation of in-
hibited complexes containing BMP-RI (Figure 6). BMP
signaling could be affected in these complexes by
blocking type II receptor recruitment, by altering signal-
ing efficiency, and by sequestering BMP-RI. By con-
trast, noggin binds BMPs as a homodimer, simulta-
neously blocking all receptor binding sites (Groppe et
al., 2002) and preventing the formation of similar recep-
tor-containing complexes. Follistatin may also be able
to engage heterodimeric TGF-β ligands with two dif-
ferent binding affinities, influencing the 1:1 and 2:1 as-
sembly pathway shown in Figure 6. Accumulating evi-
dence suggests that TGF-β heterodimers, such as
BMP-2/7 (Nishimatsu and Thomsen, 1998), BMP-4/7
(Aono et al., 1995; Suzuki et al., 1997), and Dpp/Scw
(Shimmi et al., 2005), have more potent biological activ-
ities than the corresponding homodimers (Israel et al.,
1996; Shimmi et al., 2005).
The formation of a receptor:ligand:antagonist com-
plex is not likely relevant to follistatin inhibition of ac-
tivin, since the binding affinity is greater (w100-fold)
than the activin type II receptor interaction. In the crys-Figure 6. Differing Modes of Ligand Complex
Formation and Antagonism
Schematic for the assembly of activin/BMP
ligands into signaling and nonsignaling com-
plexes. Activin conformational dynamics may
affect the cooperative binding of type I/II re-
ceptors and follistatin and also allow an in-
duced fit binding mechanism. Activin is effec-
tively neutralized by follistatin, forming a 2:1
complex that blocks receptor binding; fol-
listatin binds with much greater affinity than
activin receptors. Dotted lines in this com-
plex represent contacts between follistatin
ND and FSD3 domains that may lead to co-
operative assembly of the neutralized com-
plex. In contrast, BMPs can bind follistatin
and high-affinity type I receptor at the same
time (middle panel) and interfere with BMP
signaling. The potential for asymmetric as-
sembly of 1:1 follistatin:ligand complexes
has implications for the inhibition of hetero-
dimeric TGF-β ligands.tal structure, two follistatins contact each other in a
head-to-tail interaction that could lead to their cooper-
ative assembly onto and neutralization of activin (Figure
6). In addition, activin A undergoes profound secondary
and tertiary structure stabilization upon binding fol-
listatin, which could influence the binding of a second
follistatin through induced conformational changes in
the wrist structure. Changes in the flexibility of the ac-
tivin dimer interface and folding of the unique wrist re-
gion α helix, observed in this complex, may similarly
influence activin type I receptor binding and specificity.
In summary, we have determined the crystal structure
of activin A bound to follistatin—a TGF-β antagonist
necessary for normal development and survival. Two
follistatin molecules surround the dimeric ligand, bury-
ing its receptor binding sites and revealing that the fol-
listatin N-terminal domain is a structural mimic of the
BMP type I receptor. Follistatin contacts involve central
hydrophobic residues common to both binding and
nonbinding ligands, with surrounding amino acids de-
termining binding specificity and affinity. Activin confor-
mation and secondary structures are stabilized by fol-
listatin, consistent with a unique induced fit mechanism
for this TGF-β ligand family member. Finally, the mode
of follistatin binding differs from other antagonists, ex-
plaining its unique functional characteristics. These
structural results should enable future efforts to investi-
gate and modulate follistatin antagonism of TGF-β li-
gands in many physiological processes, including devel-
opment, cancer, tissue regeneration, and maintenance of
stem cell pluripotency.
Experimental Procedures
Activin A was produced and purified as previously described
(Thompson et al., 2003), using cell lines obtained from Genentech.
Supernatants from Chinese Hamster Ovary (CHO) cells overex-
pressing FS-288 (kindly provided by S. Shimasaki) were obtained
from the National Cell Culture Center, concentrated, dialyzed into
20 mM Tris (pH 8.0), and applied to a HiPrep 16/10 Heparin FF
column (Amersham-Pharmacia). A gradient to 1.5 M NaCl was used
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542to extract bound protein and fractions containing FS-288 were
pooled. The sample was subsequently dialyzed into 25 mM MES,
150 mM NaCl (pH 6.5) and applied to a Bio-Scale S2 cation ex-
changer (Biorad). A gradient from 150 to 1.25 M NaCl was used to
elute the protein, and fractions containing FS-288 were pooled. FS-
288 and activin A were mixed in a 2.5:1 molar ratio and incubated
for 10 min before separation on a Hiload S200 Superdex gel filtra-
tion column (Amersham-Pharmacia).
The purified complex of Activin A:FS-288 was concentrated to
14 mg/ml and utilized in crystallization trials. Diffraction quality
crystals were grown in 13%–15% PEG 3350, 200 mM malonate
(pH 7.0). Nucleation was initiated by streak seeding utilizing a cat
whisker. Crystals belong to space group P21212 and diffract X-rays
to 2.8 Å resolution via a synchrotron X-ray source. Molecular re-
placement approaches with models of activin and follistatin were
unsuccessful at solving the crystal structure. The complex struc-
ture was therefore solved by Multiple Isomorphous Replacement
with Anomalous Signal (MIRAS), using eight heavy atom com-
pounds (see Supplemental Data). Heavy atom sites were identified
by examination of anomalous difference Patterson maps and by
using the program SOLVE (Terwilliger and Berendzen, 1999). Heavy
atom parameters were refined and minor sites were added with the
program SHARP (de La Fortelle and Bricogne, 1997). Native and
heavy atom data statistics are presented in Table S2.
The Bruteptf server (http://zonker.bioc.aecom.yu.edu/cgi-bin/
inhouse/bruteptf/bruteptf.cgi) was used to rapidly position models
of activin A and FSD1 using the initial heavy atom phases. This
revealed the location of the two activin A subunits and the two
FSD1 domains. Four additional peaks were identified using a
search model consisting of a truncated FSD1, consisting of only
the Kazal protease inhibitor-like domain. At this point, it was appar-
ent that the crystallographic asymmetric unit contained 2-fold sym-
metry, and examination of the electron density map revealed that
one side of the complex was more easily interpretable. Therefore,
model building was carried out on one side of the complex and the
2-fold transformation applied to complete the complex. The initial
heavy atom-phased map was of sufficient quality to model most of
activin A, including the helix at the dimer interface, and the majority
of the three follistatin domains. Prior to building the N-terminal do-
main, improved electron density maps were generated through
several rounds of manual model building (TURBO-Frodo), model
refinement (CNS) (Brunger et al., 1998), and phase refinement
(SHARP) (de La Fortelle and Bricogne, 1997). CNS refinement was
carried out with NCS-symmetry restraints, rather than strict NCS,
based on observed improvements in the free R-factor. The best
diffraction data, which was used in model refinement, was obtained
from a crystal soaked in 5 mM IrCl6 for 9 hr. Low-occupancy Ir sites
were identified in anomalous difference maps and five Ir atoms,
along with one malonate and four 2,5 methyl pentanediol mole-
cules, were modeled. The final refinement statistics are collected
in Table 1.
Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.developmentalcell.com/cgi/content/
full/9/4/535/DC1/.
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